medigraphic.com
ISSN 1729-519X (Print)

2021, Number 4

<< Back Next >>

Revista Habanera de Ciencias Médicas 2021; 20 (4)

Reinfection, immunity and prevention of transmission of COVID-19

Guanche GH, Barbán AR

Language: Spanish
References: 11
Page: 1-4
PDF size: 1202.29 Kb.


ABSTRACT

Introduction: The duration of natural immunity generated by COVID-19 is yet to be defined, which determines the probable reinfection.
Objective: To analyze issues related to natural infection and the need to maintain prevention practices regarding a case of reinfection in a health care worker.
Case presentation: Forty-eight-year-old female patient without comorbidities who was diagnosed with COVID-19 in June 2020 and March 2021, in both cases as a mild symptomatic disease. Twenty-four hours after the onset with headache, dizziness, and dry cough, the diagnosis of SARS CoV-2 infection was confirmed by positive PCR and cycle threshold (CT) at 24.84. Nine months and nine days after original infection, and two days after receiving the BNT162b2 vaccine (Pfizer-BioNTech), the patient began with general malaise, dry cough, runny nose, and sore throat, with a positive PCR and CT of 17.61.
Conclusions: The possibility of reinfection by COVID-19 points to the need to strengthen transmission prevention practices in healthcare facilities as long as scientific evidence provides us with more effective resources for its control.


REFERENCES

  1. Kreijtz JH, Fouchier RA, Rimmelzwaan GF. Immune responses to influenza virus infection. Virus Res[Internet]. 2011 Dec [Citado 06/01/2021];162(1-2):19-30. Disponible en: http://doi.org/10.1016/j.virusres.2011.09.022

  2. Rokni M, Ghasemi V, Tavakoli Z. Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran:Comparison with SARS and MERS. Rev Med Virol [Internet]. 2020 May [Citado 06/01/2021];30(3):e2107. Disponibleen: http://doi.org/10.1002/rmv.2107

  3. Liang Y, Wang ML, Chien CS, Yarmishyn AA, Yang YP, Lai WY, et al. Highlight of Immune Pathogenic Response andHematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection. Front Immunol [Internet]. 2020 May[Citado 06/01/2021];11:1022. Disponible en: http://doi.org/10.3389/fimmu.2020.01022

  4. Glück V, Grobecker S, Tydykov L, Salzberger B, Glück T, Weidlich T, et al. SARS-CoV-2-directed antibodies persistfor more than six months in a cohort with mild to moderate COVID-19. Infection [Internet]. 2021 Mar [Citado06/01/2021];21(2):1-8. Disponible en: http://doi.org/10.1007/s15010-021-01598-6

  5. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, et al. Immunological memory to SARS-CoV-2assessed for up to 8 months after infection. Science [Internet]. 2021 Feb [Citado 06/01/2021];371(6529):eabf4063.Disponible en: http://doi.org/10.1126/science.abf4063

  6. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral Immune Responseto SARS-CoV-2 in Iceland. N Engl J Med [Internet]. 2020 Oct [Citado 06/01/2021];383(18):1724-34. Disponible en:http://doi.org/10.1056/NEJMoa2026116

  7. Poon MML, Farber DL. Lasting memories of SARS-CoV-2 infection. J Exp Med [Internet]. 2021 Apr [Citado06/01/2021];218(4):e20210210. Disponible en: http://doi.org/10.1084/jem.20210210

  8. Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccinestrategies. Nat Rev Immunol [Internet]. 2020 Oct [Citado 06/01/2021];20(10):615-32. Disponible en: http://doi.org/10.1038/s41577-020-00434-6

  9. Xiao J, Fang M, Chen Q, He B. SARS, MERS and COVID-19 among healthcare workers: A narrative review. J Infect PublicHealth [Internet]. 2020 Jun [Citado 06/01/2021];13(6):843-8. Disponible en: http://doi.org/10.1016/j.jiph.2020.05.019

  10. Suwantarat N, Apisarnthanarak A. Risks to healthcare workers with emerging diseases: lessons from MERS-CoV,Ebola, SARS, and avian flu. Curr Opin Infect Dis [Internet]. 2015 Aug [Citado 06/01/2021];28(4):349-61. Disponible en:http://doi.org/10.1097/QCO.0000000000000183

  11. World Health Organization. Infection prevention and control during health care when novel coronavirus (nCoV)infection is suspected. WHO/2019-nCoV/IPC/2020.3 [Internet] Geneva: World Health Organization; 2019 [Citado06/01/2021]. Disponible en: https://www.who.int/publications/i/item/10665-331495.




2020     |     www.medigraphic.com